Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine reported a larger full-year 2025 net loss of $212.2 million, or $6.01 per share, as it increased investment in its hematology pipeline. Research and development expenses rose to $170.6 million and selling, general and administrative costs to $65.4 million, reflecting advancing trials and commercialization preparations.
Cash, cash equivalents, and marketable securities reached $791.2 million as of December 31, 2025, boosted by $454.4 million of net proceeds from 2025 equity offerings, supporting a cash runway into 2029. The company received an FDA Complete Response Letter for bitopertin in EPP but is pursuing a traditional approval path, with Phase 3 APOLLO topline data expected in Q4 2026.
IRON — Form 144: reported insider sale activity. The filing lists Restricted Stock Units dated 02/15/2026 with a quantity of 7010 described under "Securities To Be Sold." It also records 10b5-1 sales for JEAN FRANCHI of Common stock on 02/18/2026 showing 7,081 shares and $463,572.54.
Disc Medicine, Inc. Chief Financial Officer Jean M. Franchi reported open-market sales of a total of 11,156 shares of common stock on February 17–18, 2026. The transactions were executed at weighted average prices of $62.8600, $65.0097, and $65.8889 per share, with footnotes noting sale price ranges between $64.47 and $66.38.
According to the disclosure, one of these transactions was a "sell to cover" sale used to satisfy tax withholding obligations related to previously vested restricted stock units, and did not represent a discretionary trade. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025. After these sales, Franchi directly owned 71,343 shares of Disc Medicine common stock.
Disc Medicine, Inc. Chief Legal Officer Rahul Khara reported an open-market sale of 2,853 shares of common stock at an average price of $62.86 per share on February 17, 2026. According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary sale. After this transaction, Khara directly owned 52,173 shares of Disc Medicine common stock.
Disc Medicine, Inc. Chief Commercial Officer Pamela Stephenson reported an open-market sale of 5,531 shares of common stock at $62.86 per share. According to the filing, the sale was solely to cover tax withholding on vesting restricted stock units. She now holds 80,998 shares directly.
Disc Medicine, Inc. Chief Medical Officer William Jacob Savage reported an open-market sale of 3,256 shares of common stock at $62.86 per share. According to the footnote, this was a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations from vesting restricted stock units. After the sale, he directly owned 92,589 shares.
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported an open-market sale of 3,231 shares of common stock at $62.86 per share. After the transaction, he directly owns 54,324 shares. According to the footnote, the sale was solely to cover tax withholding on vesting restricted stock units and was not a discretionary trade.
Disc Medicine, Inc. Chief Executive Officer John D. Quisel reported an open‑market sale of 13,264 shares of common stock at $62.86 per share. According to the filing, this was a "sell to cover" transaction to satisfy tax withholding obligations from vesting restricted stock units and was not a discretionary trade. After the sale, Quisel directly owned 226,064 shares of Disc Medicine common stock.
IRON reporting a Form 144 notice for proposed sale of 2,853 common shares tied to RSU vesting on 02/15/2026. The filing also records prior brokered 10b5-1 sales by Rahul Khara of 6,500 shares on 01/02/2026 for $511,471.98 and 1,000 shares on 01/20/2026 for $69,740.